Clinical Trials Sponsored by RedHill Biopharma, Inc.

Total 348 results

RedHill Biopharma Limited

Not yet recruiting

Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years

Traveler's Diarrhea
RedHill Biopharma Limited

Suspended

Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease

Covid19

United States, South Africa
RedHill Biopharma Limited

Withdrawn

Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen (Opaganib-RHB)

COVID-19 | Lung Infection

Israel
RedHill Biopharma Limited

Active, not recruiting

RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease (CleaR-MAC)

Lung Diseases | Bronchiectasis | Pulmonary Mycobacterium Avium Complex Infection

United States
RedHill Biopharma Limited

Completed

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia (COVID-19)

Coronavirus Infections

United States, Israel
RedHill Biopharma Limited

Completed

BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (GUARD)

Gastritis | Gastroenteritis

United States
RedHill Biopharma Limited

Not yet recruiting

Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years

Traveler's Diarrhea
RedHill Biopharma Limited

Completed

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

COVID-19 | Lung Infection

United States, Brazil, Colombia, Israel, Italy, Mexico, Peru, Poland, Russian Federation, United Kingdom
RedHill Biopharma Limited

Completed

A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma

Cholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic

United States
RedHill Biopharma Limited

Available

Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)

Cholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic
RedHill Biopharma Limited

Completed

Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease (MAPUS2)

Crohn Disease

United States, Canada, Czechia, Israel, New Zealand, Poland, Serbia
RedHill Biopharma Limited

Completed

Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease (MAPUS)

Crohn's Disease

United States, New Zealand, Australia, Bulgaria, Canada, Czechia, Israel, Poland, Serbia, Slovakia
RedHill Biopharma Limited

Completed

ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator (ERADICATE Hp2)

Dyspepsia | Helicobacter Pylori Infection

United States
RedHill Biopharma Limited

Completed

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105 (ERADICATE Hp)

Dyspepsia | Helicobacter Pylori Infection

United States
RedHill Biopharma Limited

Completed

Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Irritable Bowel Syndrome With Diarrhea

United States
RedHill Biopharma Limited

Completed

Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) (CEASE-MS)

Relapsing Remitting Multiple Sclerosis

Israel
RedHill Biopharma Limited
National Cancer Institute (NCI); Duke University; Apogee Biotechnology Corporation

Terminated

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma (ABC-103)

Multiple Myeloma

United States
BioPharmX, Inc.

Completed

Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel

Acne Vulgaris

United States
BioPharmX, Inc.

Unknown

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea (PRISM)

Papulopustular Rosacea

United States
BioPharmX, Inc.

Completed

Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline

Acne

United States
BioPharmX, Inc.

Completed

A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness

Fibrocystic Breast Condition (FBC)

United States, Canada
BioPharmX, Inc.

Completed

BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

Acne Vulgaris

United States
BioPharmX, Inc.

Completed

Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea

Moderate to Severe Papulopustular Rosacea

United States
BioPharmX, Inc.

Completed

BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris (OPAL)

Acne Vulgaris

United States
HC Biopharma Inc.

Recruiting

A Study of HC006 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
AiViva BioPharma, Inc.

Recruiting

Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

United States
Vitro Biopharma Inc.

Not yet recruiting

Safety & Efficacy of AlloRx SC® in PTHS Patients

Pitt Hopkins Syndrome
Ansun Biopharma, Inc.

Recruiting

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

COVID-19 | Lower Respiratory Tract Infection | Immunocompromised | Parainfluenza

United States, Australia, China, Denmark, France, Hong Kong, Korea, Republic of, Taiwan
Acrotech Biopharma Inc.

Active, not recruiting

A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Aytu BioPharma, Inc.

Withdrawn

A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0

Male Infertility

United States
Nitto BioPharma, Inc.

Active, not recruiting

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | Non-Small Cell Lung Cancer

United States
AiViva BioPharma, Inc.

Completed

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

Keloid

United States
Staidson Biopharma Inc.

Completed

The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects

Healthy

United States
AiViva BioPharma, Inc.

Completed

A Safety and Efficacy Study to Evaluate Wound Healing

Wound Heal

United States
Acrotech Biopharma Inc.

Withdrawn

Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn

Non Hodgkin's Lymphoma
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Cutaneous T-cell Lymphoma

United States
Acrotech Biopharma Inc.

Completed

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma

United Kingdom, United States
Acrotech Biopharma Inc.

Completed

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Mycosis Fungoides | Sezary Syndrome | Cutaneous T-cell Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma

United States, Italy
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Carcinoma, Transitional Cell | Bladder Cancer | Bladder Neoplasm

Spain, France, Belgium, United States, Argentina, Croatia
Acrotech Biopharma Inc.

Completed

Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States
Alios Biopharma Inc.

Completed

First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Chronic Hepatitis C

France, Moldova, Republic of, Georgia
Ansun Biopharma, Inc.

Completed

Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza

Influenza

United States
Alios Biopharma Inc.

Completed

A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants

Hepatitis B

New Zealand
Therapure Biopharma Inc

Unknown

Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Micelle BioPharma Inc

Unknown

A Sickle CEll Disease ComplicatioN Trial (ASCENT)

Sickle Cell Disease
Oncolys BioPharma Inc

Unknown

A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer

Esophageal Cancer

Japan
Alios Biopharma Inc.

Terminated

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers

Healthy

United Kingdom
Alios Biopharma Inc.

Terminated

Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

Hepatitis B | Chronic Hepatitis B | Viral Hepatitis B

New Zealand
Ansun Biopharma, Inc.

Completed

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS181-2-05)

Parainfluenza

United States
Alios Biopharma Inc.

Completed

A Study to Assess the PK of AL-794 Formulations in Healthy Subjects

Influenza

United Kingdom

3

Subscribe